Compare Stocks: MNOV, EYPT, PALI, and IKT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EYPT Eyepoint Pharmaceuticals	$3.86 +11.7%	$9.22	$3.41 ▼ $19.11	$333.20M	1.63	2.03 million shs	4.75 million shs
IKT Inhibikase Therapeutics	$2.30 -0.6%	$2.33	$1.33 ▼ $2.61	$320.24M	0.95	1.13 million shs	299,353 shs
MNOV MediciNova	$3.40 +35.0%	$1.46	$1.17 ▼ $3.90	$167.84M	0.63	96,475 shs	6.16 million shs
PALI Palisade Bio	$1.70 +0.3%	$2.02	$0.57 ▼ $2.86	$293.65M	1.53	3.60 million shs	3.31 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EYPT Eyepoint Pharmaceuticals	-5.74%	-20.51%	-29.16%	-74.59%	-74.63%
IKT Inhibikase Therapeutics	0.00%	-4.15%	-3.35%	+26.23%	+48.08%
MNOV MediciNova	+24.75%	+40.78%	+90.91%	+90.91%	+101.60%
PALI Palisade Bio	-16.34%	-17.56%	-21.40%	-9.63%	+180.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EYPT Eyepoint Pharmaceuticals	$3.86 +11.7%	$9.22	$3.41 ▼ $19.11	$333.20M	1.63	2.03 million shs	4.75 million shs
IKT Inhibikase Therapeutics	$2.30 -0.6%	$2.33	$1.33 ▼ $2.61	$320.24M	0.95	1.13 million shs	299,353 shs
MNOV MediciNova	$3.40 +35.0%	$1.46	$1.17 ▼ $3.90	$167.84M	0.63	96,475 shs	6.16 million shs
PALI Palisade Bio	$1.70 +0.3%	$2.02	$0.57 ▼ $2.86	$293.65M	1.53	3.60 million shs	3.31 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EYPT Eyepoint Pharmaceuticals	-5.74%	-20.51%	-29.16%	-74.59%	-74.63%
IKT Inhibikase Therapeutics	0.00%	-4.15%	-3.35%	+26.23%	+48.08%
MNOV MediciNova	+24.75%	+40.78%	+90.91%	+90.91%	+101.60%
PALI Palisade Bio	-16.34%	-17.56%	-21.40%	-9.63%	+180.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EYPT Eyepoint Pharmaceuticals	2.27	Hold	$25.70	566.67% Upside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	135.29% Upside
MNOV MediciNova	2.71	Moderate Buy	$7.75	127.74% Upside
PALI Palisade Bio	3.00	Buy	$9.00	430.97% Upside

Current Analyst Ratings Breakdown

Latest MNOV, EYPT, PALI, and IKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	MNOV MediciNova	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
9/2/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	EYPT Eyepoint Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$20.00 ➝ $4.00
9/1/2026	EYPT Eyepoint Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	EYPT Eyepoint Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$17.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Sector Perform	$5.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
8/17/2026	EYPT Eyepoint Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	EYPT Eyepoint Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
8/17/2026	EYPT Eyepoint Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EYPT Eyepoint Pharmaceuticals	$31.37M	10.59	N/A	N/A	$3.70 per share	1.04
IKT Inhibikase Therapeutics	$260K	1,231.71	N/A	N/A	$2.30 per share	1.00
MNOV MediciNova	$410K	408.53	N/A	N/A	$0.85 per share	4.00
PALI Palisade Bio	$250K	1,181.55	N/A	N/A	$0.87 per share	1.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EYPT Eyepoint Pharmaceuticals	-$231.96M	-$3.74	N/A	N/A	N/A	-10,994.73%	-135.81%	-108.35%	11/4/2026 (Estimated)
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
MNOV MediciNova	-$12M	-$0.21	N/A	N/A	N/A	-1,168.70%	-26.51%	-24.39%	11/12/2026 (Estimated)
PALI Palisade Bio	-$16.78M	-$0.48	N/A	N/A	N/A	N/A	-33.47%	-31.79%	11/9/2026 (Estimated)

Latest MNOV, EYPT, PALI, and IKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MNOV MediciNova	-$0.0633	-$0.05	+$0.0133	-$0.05	$0.08 million	$0.46 million
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/10/2026	Q2 2026	PALI Palisade Bio	-$0.0522	-$0.05	+$0.0022	-$0.05	$0.50 million	$0.50 million
8/5/2026	Q2 2026	EYPT Eyepoint Pharmaceuticals	-$1.01	-$1.09	-$0.08	-$0.2720	$0.45 million	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EYPT Eyepoint Pharmaceuticals	N/A	4.50	4.46
IKT Inhibikase Therapeutics	N/A	15.82	15.82
MNOV MediciNova	N/A	8.75	8.75
PALI Palisade Bio	N/A	24.26	24.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EYPT Eyepoint Pharmaceuticals	99.41%
IKT Inhibikase Therapeutics	3.81%
MNOV MediciNova	9.90%
PALI Palisade Bio	11.79%

Insider Ownership

Company	Insider Ownership
EYPT Eyepoint Pharmaceuticals	5.13%
IKT Inhibikase Therapeutics	7.10%
MNOV MediciNova	14.00%
PALI Palisade Bio	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EYPT Eyepoint Pharmaceuticals	214	86.21 million	81.79 million	Optionable
IKT Inhibikase Therapeutics	35	139.54 million	129.63 million	N/A
MNOV MediciNova	6	49.22 million	42.33 million	Optionable
PALI Palisade Bio	14	174.27 million	174.15 million	Not Optionable

MNOV, EYPT, PALI, and IKT Headlines

Recent News About These Companies

Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16 at 7:00 PM | seekingalpha.com

Palisade Bio出席摩根士丹利大会：加速推进炎症性肠病布局

September 16 at 2:11 PM | cn.investing.com

Palisade Bio, Inc. $PALI Shares Acquired by Wellington Management Group LLP

September 9, 2026 | marketbeat.com

Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Rating of "Buy" by Brokerages

September 8, 2026 | marketbeat.com

Palisade Bio to Participate in Upcoming Investor Conferences

September 3, 2026 | globenewswire.com

10,436,760 Shares in Palisade Bio, Inc. $PALI Bought by BlackRock Inc.

September 3, 2026 | marketbeat.com

Jupiter Topco LLC Invests $22.39 Million in Palisade Bio, Inc. $PALI

August 29, 2026 | marketbeat.com

Artia Global Partners LP Takes $4.16 Million Position in Palisade Bio, Inc. $PALI

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Palisade Bio, Inc. $PALI

August 26, 2026 | marketbeat.com

Palisade Bio Q3 EPS Decreased by Brookline Capital Markets

August 18, 2026 | marketbeat.com

Brokerages Set Palisade Bio, Inc. (NASDAQ:PALI) Price Target at $9.00

August 17, 2026 | defenseworld.netD

Palisade Bio, Inc.: Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

August 11, 2026 | finanznachrichten.de

Analysts’ Top Healthcare Picks: Palisade Bio (PALI), Sarepta Therapeutics (SRPT)

August 11, 2026 | theglobeandmail.com

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

August 10, 2026 | finance.yahoo.com

Palisade Bio Reports Q2 2026 Results, Advances PALI-2108 Into Phase 2 Development for Ulcerative Colitis and Crohn’s Disease

August 10, 2026 | quiverquant.comQ

Palisade Bio jumps following Oppenheimer outperform initiation

July 23, 2026 | msn.com

Robert Jr. Baltera Acquires 20,000 Shares of Palisade Bio (NASDAQ:PALI) Stock

July 11, 2026 | insidertrades.com

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

July 10, 2026 | markets.businessinsider.com

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

July 10, 2026 | globenewswire.com

Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets

July 10, 2026 | seekingalpha.com

Insider Buying: Palisade Bio (NASDAQ:PALI) Director Purchases 20,000 Shares

July 9, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV, EYPT, PALI, and IKT Company Descriptions

Eyepoint Pharmaceuticals NASDAQ:EYPT

$3.86 +0.41 (+11.74%)

As of 02:54 PM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Inhibikase Therapeutics NASDAQ:IKT

$2.30 -0.02 (-0.65%)

As of 02:54 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

MediciNova NASDAQ:MNOV

$3.40 +0.88 (+35.04%)

As of 02:54 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Palisade Bio NASDAQ:PALI

$1.70 +0.01 (+0.30%)

As of 02:54 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNOV, EYPT, PALI, and IKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNOV, EYPT, PALI, and IKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNOV, EYPT, PALI, and IKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV, EYPT, PALI, and IKT Company Descriptions

Eyepoint Pharmaceuticals NASDAQ:EYPT

Inhibikase Therapeutics NASDAQ:IKT

MediciNova NASDAQ:MNOV

Palisade Bio NASDAQ:PALI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNOV, EYPT, PALI, and IKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNOV, EYPT, PALI, and IKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNOV, EYPT, PALI, and IKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV, EYPT, PALI, and IKT Company Descriptions

Eyepoint Pharmaceuticals NASDAQ:EYPT

Inhibikase Therapeutics NASDAQ:IKT

MediciNova NASDAQ:MNOV

Palisade Bio NASDAQ:PALI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools